Galien Golden Jubilee Forum – USA2021

Oct. 28th, 2021
8AM – 9AM

In-person registrationLive broadcast registration

MaryAnne Rizk, Chief Strategy Officer, Medable

Robert Califf, Head of Clinical Policy & Strategy, Verify and Google Health; Adjunct Professor, Duke University & Stanford University; former FDA Deputy Commissioner to President Barack Obama
Tony Clapsis, Vice President, CVS Clinical Trial Services
Cristina Duran, Chief Digital Health Officer, R&D, AstraZeneca
Sebastian Guth, President of Bayer Pharmaceuticals, Americas Region
Michelle Longmire, Co-founder & CEO, Medable
Andy Plump, President, Research & Development, Takeda Pharmaceuticals Company Ltd.


The Future is Decentralized: How the Paradigm Has Changed in Modernizing Medicine


For decades, clinical research was conducted in person across hospitals, clinics, and research institutions worldwide. While this structure proved effective in helping create countless treatments and cures over the 20th and 21st centuries, it was not without its difficulties. The use of physical research locations ensured that participation was centralized around trial sites’ themselves, limiting access to those who could participate. Additionally, the need to create more specialized cures and treatments combined with the limitations inherent in this physical-only approach helped drive the steep increases seen in cost and clinical timelines.

Then in March of 2020, the future of clinical trials and our world was forever changed. As hospitals, on-site clinics, and countries across the globe began to shut down due to COVID-19, it became obvious that a new clinical paradigm had arrived. Born from necessity, a patient-centered approach took hold as our industry paused, assessed its capabilities, and then re-emerged with a network of decentralized technologies, partners, and services that would bring trials into the homes of patients worldwide. This was shift was monumental, as it was the first time the industry had moved en masse to ensure trials were no longer bound to physical locations.

As a result, decentralized and hybrid clinical trial technologies and approaches have moved out of keynote speeches, webinars, and articles, finding residence instead across thousands of trials around the world. This includes trials once thought impossible using DCT, as shown by leading Everest ranked DCT provider Medable, in their ability to enroll more than 1,000 patients Oncology patients in a single day. Now, as more organizations implement, improve, and realize the benefits of decentralization it’s clear that there’s “no going back.”

What does this mean for you, your organization, and the future of your trials?

Join us, as a panel of industry veterans discusses the impact and implications of a new patient-centric era focused around decentralized and hybrid solutions. Attendees will walk away understanding:

  • The impact that COVID-19 had on the way trials are designed and conducted;
  • What technologies have brought us closer to the patient, and what benefits we’ve gained as a result;
  • How patient-centered approaches will reshape the future of research; and
  • What you can do to prepare, or evolve your hybrid and decentralized approach